clinical trials retatrutide Significantly Reduces Visceral Fat in What Is Retatrutide And How

A GLP-1 agonist is a drug that initiates a response to make you feel full, decrease appetite and release insulin

For information on regulatory access in Canada, see our guide to retatrutide availability in Canada

Coverage often limits to patients with a BMI of 30 or higher (or 27+ with weight-related comorbidities)

Transdermal patches generally require application to areas of skin that provide consistent drug absorption whilst minimising irritation and mechanical disruption

Who qualifies for the GLP-1 Bridge program

These drugs work by mimicking the hormone glucagon-like peptide-1 (GLP-1), which regulates appetite, slows gastric emptying, and promotes insulin secretion